ATARA Biotherapeutics (ATRA) Misses Q2 EPS by 10c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/5/2026
- Nasdaq notches record high close as investors focus on earnings
- Oil slips on rising Mideast crude exports, G7 stocks release
- Intel stock slides as TSMC explores Terafab tie-up, analyst flags share losses
- Schneider Electric to acquire PTC for $22.6 billion in all-cash deal
- Five things to watch in markets in the week ahead
Tweet
Share
E-mailGet Alerts ATRA Hot Sheet
Join SI Premium – FREE
ATARA Biotherapeutics (NASDAQ: ATRA) reported Q2 EPS of ($0.32), $0.10 worse than the analyst estimate of ($0.22). Revenue for the quarter came in at $630 thousand versus the consensus estimate of $2.55 million.
For earnings history and earnings-related data on ATARA Biotherapeutics (ATRA) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- SpaceX (SPCX) PT Raised to $230 at Goldman Sachs ahead of earnings release
- Lockheed Martin wins $209M Navy electronic warfare contract
- Better Home & Finance moves toward Birmingham Bank sale
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
